Tafamidis
Back to searchMolecule Structure
Scientific Name
Tafamidis
Description of the Drug
Tafamidis is a medication used to treat transthyretin-mediated amyloidosis.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11644
http://www.drugbank.ca/drugs/DB11644
Brand Name(s)
Vyndamax, Vyndaqel
Company Owner(s)
Foldrx Pharmaceuticals Llc A Wholly Owned Sub Of Pfizer Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Transthyretin | SINGLE PROTEIN | STABILISER | CHEMBL3194 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL442508 | |||
| Human Metabolome Database | HMDB0258677 | |||
| DrugBank | DB11644 | |||
| PubChem: Thomson Pharma | 16061373 | |||
| PubChem | 11001318 | |||
| LINCS | LSM-45558 | |||
| Nikkaji | J1.930.213J | |||
| PDBe | 3MI | |||
| BindingDB | 50197883 | |||
| EPA CompTox Dashboard | DTXSID00208185 | |||
| DrugCentral | 4192 | |||
| ChemicalBook | CB52484674 | |||
| Guide to Pharmacology | 8378 | |||
| rxnorm | TAFAMIDIS | VYNDAQEL | TAFAMIDIS MEGLUMINE | VYNDAMAX |
| ChEBI | 78538 | |||
| ZINC | ZINC000043206271 |
